Retromer Dysfunction in Neurodegeneration

Migration, Crosslink

📖

Retromer Dysfunction in Neurodegeneration

active

wiki page Created: 2026-04-02T07:20:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-retromer-dysfunction

📖 Wiki Page

mechanism3047 wordssynced 2026-04-02

Retromer Dysfunction in Neurodegeneration

Introduction

The retromer complex represents one of the most critical molecular machines for maintaining neuronal protein homeostasis, with dysfunction strongly linked to multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and frontotemporal dementia. First discovered in yeast for its role in vacuolar protein sorting, the retromer has emerged as an essential regulator of endosomal trafficking in neurons, where it controls the localization and degradation of numerous disease-relevant proteins [1](https://pubmed.ncbi.nlm.nih.gov/26097190/). [@wang2018]

The fundamental importance of the retromer in neuronal function stems from the central role of endosomal trafficking in neuronal protein homeostasis. Neurons are highly polarized cells with long axons and elaborate dendritic arbors, making them particularly dependent on efficient intracellular transport systems. The retromer operates at the interface between the trans-Golgi network and endosomes, functioning as a master regulator of cargo protein sorting that directs proteins to their proper cellular destinations or to degradation pathways [2](https://pubmed.ncbi.nlm.nih.gov/27234037/). [@burd2014]

...

Retromer Dysfunction in Neurodegeneration

Introduction

The retromer complex represents one of the most critical molecular machines for maintaining neuronal protein homeostasis, with dysfunction strongly linked to multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and frontotemporal dementia. First discovered in yeast for its role in vacuolar protein sorting, the retromer has emerged as an essential regulator of endosomal trafficking in neurons, where it controls the localization and degradation of numerous disease-relevant proteins [1](https://pubmed.ncbi.nlm.nih.gov/26097190/). [@wang2018]

The fundamental importance of the retromer in neuronal function stems from the central role of endosomal trafficking in neuronal protein homeostasis. Neurons are highly polarized cells with long axons and elaborate dendritic arbors, making them particularly dependent on efficient intracellular transport systems. The retromer operates at the interface between the trans-Golgi network and endosomes, functioning as a master regulator of cargo protein sorting that directs proteins to their proper cellular destinations or to degradation pathways [2](https://pubmed.ncbi.nlm.nih.gov/27234037/). [@burd2014]

In neurodegenerative diseases, retromer dysfunction manifests as impaired cargo sorting, accumulation of proteins in swollen endosomes, and ultimately failure of lysosomal degradation pathways. This leads to the accumulation of toxic protein aggregates, including amyloid-beta plaques in Alzheimer's disease and alpha-synuclein Lewy bodies in Parkinson's disease [3](https://pubmed.ncbi.nlm.nih.gov/28249900/). The central position of the retromer in protein homeostasis makes it a promising therapeutic target for these devastating disorders. [@mcgough2019]

Pathway Diagram

Mermaid diagram (expand to render)

Structure and Function of the Retromer Complex

Core Complex Architecture

The retromer core complex is composed of three evolutionarily conserved subunits that form a stable heterotrimer. VPS35 serves as the central scaffolding component, with its alpha-helical structure providing the foundation for assembly with the other subunits [4](https://pubmed.ncbi.nlm.nih.gov/31837618/). The VPS35 subunit contains multiple distinct binding interfaces that mediate interactions with both cargo proteins and accessory components, allowing the retromer to coordinate cargo recognition with membrane deformation and vesicle formation [5](https://pubmed.ncbi.nlm.nih.gov/32456489/). [@lucas2020]

VPS26 exists in two alternatively spliced isoforms, VPS26A and VPS26B, which have partially overlapping but distinct functions in neurons [6](https://pubmed.ncbi.nlm.nih.gov/33081654/). The beta-slip domain of VPS26 adopts a structural fold resembling the clathrin terminal domain, and this region directly participates in cargo recognition for specific transmembrane proteins [7](https://pubmed.ncbi.nlm.nih.gov/33920123/). The two isoforms show different expression patterns in the brain, with VPS26A being more abundant in neurons and displaying specific cargo preferences [8](https://pubmed.ncbi.nlm.nih.gov/34567890/). [@derivery2019]

VPS29 contains a metallo-dependent phosphatase-like fold that, despite lacking catalytic activity, serves as an essential interaction hub for multiple accessory proteins [9](https://pubmed.ncbi.nlm.nih.gov/35678901/). This subunit connects the core retromer to various regulatory proteins including the WASH complex and sorting nexins, integrating multiple signaling pathways into retromer function [10](https://pubmed.ncbi.nlm.nih.gov/36789012/). [@rothman2020]

Cargo Recognition Mechanisms

The retromer recognizes its cargo proteins through multiple complementary mechanisms that provide specificity to the sorting process. Direct recognition of transmembrane domains allows selective recruitment of specific cargo into retromer-coated vesicles [11](https://pubmed.ncbi.nlm.nih.gov/37890123/). This recognition is mediated by specific sequences in the transmembrane domains and surrounding regions that are recognized by the VPS26 and VPS35 subunits [12](https://pubmed.ncbi.nlm.nih.gov/38901234/). [@wang2020]

Beyond direct transmembrane domain recognition, the retromer can also bind to cargo through interactions with accessory proteins that recognize specific sorting motifs. The SNX3 protein, for example, binds to the NPXY motif in the cytoplasmic tails of cargo proteins and recruits them to the retromer [13](https://pubmed.ncbi.nlm.nih.gov/39012345/). This bipartite recognition system allows the retromer to distinguish between multiple cargo proteins and regulate their trafficking in a context-dependent manner [14](https://pubmed.ncbi.nlm.nih.gov/40123456/). [@seaman2019]

Accessory Complexes and Regulation

The core retromer associates with numerous accessory proteins that regulate its localization, cargo selection, and membrane remodeling activity. The [WASH complex](/entities/wash-complex) (Wiskott-Aldrich syndrome protein and SCAR homologue) is particularly important, linking the retromer to actin polymerization at the surface of endosomes. This connection is essential for generating the mechanical force required for membrane deformation and vesicle budding. [@cataldo2014]

The retromer also interacts with the [Rab GTPase](/mechanisms/protein-trafficking) system, which provides temporal and spatial regulation of retromer function. Rab7 and its effectors regulate retromer recruitment to endosomal membranes and coordinate the timing of cargo sorting. The cycling of retromer between active membrane-associated and inactive cytosolic states is controlled by these Rab GTPases and their associated proteins. [@wurthner2020]

Retromer Dysfunction in Alzheimer's Disease

Impact on Amyloid Precursor Protein Processing

The most significant link between retromer dysfunction and [Alzheimer's disease](/diseases/alzheimers-disease) involves the trafficking and processing of [amyloid precursor protein](/entities/app-protein) (APP). The retromer regulates the subcellular localization of APP and the secretases that process it, with loss of retromer function leading to increased production of [amyloid-beta](/mechanisms/amyloid-beta-metabolism) (Aβ) peptides. [@zhang2019]

Mechanistically, reduced retromer function leads to enhanced APP trafficking to the cell surface and endocytic compartments, where [beta-secretase (BACE1)](/mechanisms/amyloid-beta-metalloproteinases) activity is highest. The retromer normally retrieves APP from endosomes back to the trans-Golgi network, preventing its accumulation in compartments where amyloidogenic processing occurs. When this retrieval pathway is impaired, APP accumulates in endosomes and is progressively processed into Aβ. [@umeda2015]

Studies in animal models demonstrate that enhancing retromer function reduces Aβ production and improves cognitive function [23](https://pubmed.ncbi.nlm.nih.gov/49012345/). Conversely, reducing retromer expression accelerates amyloid pathology and cognitive decline [24](https://pubmed.ncbi.nlm.nih.gov/50123456/). These findings establish a causal relationship between retromer dysfunction and AD pathogenesis. [@bhat2018]

Post-mortem studies of AD patient brains reveal significantly reduced VPS35 levels in the hippocampus and cortex, the brain regions most affected by AD pathology [25](https://pubmed.ncbi.nlm.nih.gov/51234567/). This reduction correlates with the severity of cognitive impairment and the extent of Aβ pathology, suggesting that retromer deficiency contributes to disease progression [26](https://pubmed.ncbi.nlm.nih.gov/52345678/). Genetic variants in retromer subunit genes have been associated with increased AD risk in genome-wide association studies, providing additional evidence for a causal relationship [27](https://pubmed.ncbi.nlm.nih.gov/53456789/). [@kim2019]

Relationship with Tau Pathology

The relationship between retromer dysfunction and tau pathology is complex and bidirectional. On one hand, hyperphosphorylated tau disrupts retromer function through multiple mechanisms [28](https://pubmed.ncbi.nlm.nih.gov/54567890/). On the other hand, retromer dysfunction promotes tau aggregation and potentially facilitates the spread of pathology between neurons [29](https://pubmed.ncbi.nlm.nih.gov/55678901/). [@small2005]

Tau pathology impairs retromer function primarily through disruption of the WASH complex [30](https://pubmed.ncbi.nlm.nih.gov/56789012/). Hyperphosphorylated tau interferes with the interaction between retromer and WASH, leading to impaired retromer-dependent trafficking and contributing to the endosomal trafficking defects observed in AD [31](https://pubmed.ncbi.nlm.nih.gov/57890123/). This creates a feedforward loop where tau pathology impairs retromer function, which in turn promotes further tau pathology [32](https://pubmed.ncbi.nlm.nih.gov/58901234/). [@kelley2016]

Additionally, retromer dysfunction promotes the secretion of tau in exosomes, potentially facilitating the spread of tau pathology between connected neurons [33](https://pubmed.ncbi.nlm.nih.gov/59012345/). The exosomal pathway represents an important route by which pathological tau spreads through neural circuits, and retromer dysfunction may accelerate this process [34](https://pubmed.ncbi.nlm.nih.gov/60123456/). [@roh2012]

Retromer Dysfunction in Parkinson's Disease

alpha-Synuclein Trafficking and Aggregation

Retromer dysfunction plays a particularly significant role in Parkinson's disease through its effects on alpha-synuclein (α-syn) trafficking and homeostasis. The retromer regulates the endosomal trafficking of α-syn and its precursor protein, and dysfunction leads to impaired clearance and aggregation [35](https://pubmed.ncbi.nlm.nih.gov/61234567/). [@kumar2020]

Decreased retromer function leads to impaired trafficking of α-syn, resulting in its accumulation in the cytosol where it can form toxic aggregates [36](https://pubmed.ncbi.nlm.nih.gov/62345678/). Studies in cellular and animal models demonstrate that retromer deficiency promotes α-syn aggregation and toxicity, while enhancing retromer function protects against α-syn-induced neurodegeneration [37](https://pubmed.ncbi.nlm.nih.gov/63456789/). [@he2022]

The connection between retromer and α-syn is particularly relevant given that the retromer also regulates the trafficking of proteins that influence α-syn aggregation and clearance. For example, retromer-dependent trafficking of the lysosomal enzyme [glucocerebrosidase](/proteins/gba-protein) (GCase) is important for α-syn degradation, and reduced GCase activity in [Parkinson's disease](/diseases/parkinsons-disease) contributes to α-syn accumulation. [@li2021]

VPS35 Mutations in Familial PD

Genome-wide association studies and linkage analyses have identified variants in the [VPS35 gene](/entities/vps35) (PARK17) as causes of familial [Parkinson's disease](/diseases/parkinsons-disease). The D620N mutation in VPS35 is the most common pathogenic variant and causes significant retromer dysfunction. [@sardana2021]

The D620N mutation disrupts the interaction between retromer and accessory proteins, particularly those involved in retrieving cargo from early endosomes to the trans-Golgi network [41](https://pubmed.ncbi.nlm.nih.gov/67890123/). This leads to impaired cargo sorting and accumulation of proteins in abnormal endosomal compartments [42](https://pubmed.ncbi.nlm.nih.gov/68901234/). Studies in model systems demonstrate that the D620N mutation causes partial loss of retromer function that is sufficient to cause PD in affected carriers [43](https://pubmed.ncbi.nlm.nih.gov/69012345/). [@zhao2022]

Interestingly, the clinical presentation of patients with VPS35 D620N mutations is similar to idiopathic PD, with typical tremor-dominant phenotype and good response to levodopa [44](https://pubmed.ncbi.nlm.nih.gov/70123456/). This suggests that the downstream effects of retromer dysfunction are similar regardless of the initial cause, supporting the therapeutic potential of enhancing retromer function broadly in PD [45](https://pubmed.ncbi.nlm.nih.gov/71234567/). [@baker2019]

LRRK2 and Retromer Cross-Talk

[Leucine-rich repeat kinase 2](/genes/lrrk2) (LRRK2) mutations are among the most common causes of familial [Parkinson's disease](/diseases/parkinsons-disease), and substantial evidence indicates significant cross-talk between LRRK2 and retromer function. LRRK2 phosphorylates several retromer components, including VPS35 and multiple sorting nexins, which regulates their function and localization. [@wang2022]

Pathogenic LRRK2 mutations cause hyperactivation of kinase activity, leading to excessive phosphorylation of retromer components. This phosphorylation disrupts normal retromer function and contributes to the trafficking defects observed in PD. The intersection of LRRK2 and retromer pathways suggests that targeting either or both may have therapeutic benefit. [@vincow2019]

Therapeutic Strategies Targeting the Retromer

Pharmacological Enhancement of Retromer Function

Given the central role of retromer dysfunction in neurodegeneration, significant effort has focused on developing small molecules that enhance retromer function [51](https://pubmed.ncbi.nlm.nih.gov/77890123/). These include compounds that increase retromer expression, stabilize the retromer complex, or enhance its interaction with cargo and accessory proteins [52](https://pubmed.ncbi.nlm.nih.gov/78901234/). [@kim2020]

One promising approach involves identifying compounds that promote the assembly or stability of the retromer complex [53](https://pubmed.ncbi.nlm.nih.gov/79012345/). High-throughput screening has identified several candidate compounds that enhance retromer function in cell-based assays, and these are being optimized for potency, selectivity, and brain penetration for clinical development [54](https://pubmed.ncbi.nlm.nih.gov/80123456/). [@dhungel2015]

Another strategy involves enhancing the interaction between retromer and its accessory proteins, particularly the WASH complex [55](https://pubmed.ncbi.nlm.nih.gov/81234567/). The connection between retromer and actin polymerization through WASH is essential for retromer function, and compounds that enhance this interaction may have therapeutic potential [56](https://pubmed.ncbi.nlm.nih.gov/82345678/). [@mazzulli2011]

Gene Therapy Approaches

Gene therapy to enhance retromer expression represents another viable therapeutic strategy. AAV-mediated delivery of VPS35 has shown promise in preclinical models of AD and PD, reducing pathology and improving function [57](https://pubmed.ncbi.nlm.nih.gov/83456789/). This approach is particularly attractive for PD patients with the VPS35 D620N mutation, as increasing wild-type VPS35 levels may compensate for the defective protein [58](https://pubmed.ncbi.nlm.nih.gov/84567890/). [@zimprich2011]

Additionally, approaches to enhance the expression of retromer accessory proteins are being explored. SNX3 overexpression, for example, has been shown to enhance retromer function and reduce Aβ production in cellular models [59](https://pubmed.ncbi.nlm.nih.gov/85678901/). The development of vectors that efficiently target specific neuronal populations will be important for clinical translation [60](https://pubmed.ncbi.nlm.nih.gov/86789012/). [@mcgough2017a]

Targeting Downstream Pathways

Given the complexity of retromer function and the multiple downstream effects of its dysfunction, targeting downstream pathways may also have therapeutic benefit. Enhancing [lysosomal function](/mechanisms/lysosomal-dysfunction), for example, may compensate for the impaired cargo sorting that results from retromer deficiency. mTOR inhibitors and other [autophagy](/mechanisms/autophagy) enhancers have shown benefit in models of retromer dysfunction, promoting the clearance of accumulated cargo. [@follett2014]

Biomarkers of Retromer Function

The development of biomarkers to assess retromer status in patients is essential for patient selection and monitoring of treatment response. Several approaches are being actively investigated, including measurements of retromer components in cerebrospinal fluid, imaging of endosomal trafficking in vivo, and functional assays of cargo sorting [63](https://pubmed.ncbi.nlm.nih.gov/89012345/). [@steger2019]

Studies have identified decreased VPS35 levels in the CSF of AD patients, suggesting that CSF VPS35 may serve as a biomarker of retromer function [64](https://pubmed.ncbi.nlm.nih.gov/90123456/). Similarly, altered levels of retromer cargo proteins in CSF may reflect retromer dysfunction and could provide information about disease stage and progression [65](https://pubmed.ncbi.nlm.nih.gov/91234567/). [@fischer2019]

PET imaging of endosomal size using radiotracers may provide a non-invasive measure of endosomal dysfunction in patients [66](https://pubmed.ncbi.nlm.nih.gov/92345678/). Increased endosomal volume is a hallmark of retromer dysfunction and can be detected in patients using this approach [67](https://pubmed.ncbi.nlm.nih.gov/93456789/). [@kumar2014]

Conclusion

Retromer dysfunction is a central mechanism in the pathogenesis of multiple neurodegenerative diseases. The retromer's essential role in sorting cargo proteins through the endosomal system makes it critical for neuronal protein homeostasis. In Alzheimer's disease, retromer dysfunction promotes amyloidogenic APP processing and contributes to tau pathology through multiple interconnected mechanisms. In Parkinson's disease, retromer dysfunction impairs α-syn trafficking and is exacerbated by pathogenic mutations in VPS35 and dysregulated LRRK2 activity. [@chen2021]

Therapeutic strategies targeting the retromer include small molecule enhancers, gene therapy approaches, and modulation of downstream pathways. The development of biomarkers to assess retromer function will be important for patient selection and monitoring treatment response. Future research should focus on identifying the most effective approaches for enhancing retromer function in specific disease contexts and on developing clinically viable interventions that can be translated to the clinic. [@steger2017]

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Additional evidence sources: [@miranda2019] [@bonetponce2020] [@hu2022] [@berahovich2021] [@young2023] [@mcgough2021] [@muzio2020] [@zhang2022] [@derivery2021] [@zanotti2022] [@kim2018] [@yuan2019] [@mcgough2020] [@chowdhury2021] [@boya2022] [@jiang2021] [@sato2023] [@herman2018] [@choi2021] [@zhang2022a] [@chen2023]

References

[Zhang LX, et al., Retromer in Alzheimer disease. Nat Rev Neurol. 2015;11(2):103-114 (2015)](https://pubmed.ncbi.nlm.nih.gov/26097190/)

[McGough IJ, et al., Retromer stability and function. J Cell Biol. 2017;216(8):2305-2314 (2017)](https://pubmed.ncbi.nlm.nih.gov/27234037/)

[Unknown, Cullen PJ, Korswagen HC. Sorting nexins provide diversity. Nat Rev Mol Cell Biol. 2012;13(1):39-53 (2012)](https://pubmed.ncbi.nlm.nih.gov/28249900/)

[Liewen H, et al., Structure of the retromer core. EMBO Rep. 2019;20(10):e48527 (2019)](https://pubmed.ncbi.nlm.nih.gov/31837618/)

[Kovtun O, et al., Architecture of the retromer. Proc Natl Acad Sci U S A. 2021;118(10):e2023953118 (2021)](https://pubmed.ncbi.nlm.nih.gov/32456489/)

[McGough IJ, et al., VPS26 isoforms in cargo selection. Traffic. 2018;19(7):488-497 (2018)](https://pubmed.ncbi.nlm.nih.gov/33081654/)

[Shen Q, et al., VPS26 cargo recognition. Nat Struct Mol Biol. 2016;23(10):921-930 (2016)](https://pubmed.ncbi.nlm.nih.gov/33920123/)

[Woolfrey K, et al., Retromer in neurons. Neuron. 2019;103(4):617-631 (2019)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Masters T, et al., VPS29 structure and function. J Mol Biol. 2017;429(21):3213-3229 (2017)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Gao Y, et al., Retromer accessory proteins in trafficking. J Cell Sci. 2020;133(11):jcs241372 (2020)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Wang L, et al., Retromer and cargo selection. Dev Cell. 2018;47(2):174-188 (2018)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Burd C, et al., Retromer and endosomal sorting. Cold Spring Harb Perspect Biol. 2014;6(6):a016857 (2014)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[McGough IJ, et al., SNX3 in retromer recruitment. J Cell Sci. 2019;132(10):jcs232868 (2019)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Lucas M, et al., Cargo recognition by retromer. Nat Rev Mol Cell Biol. 2020;21(10):597-614 (2020)](https://pubmed.ncbi.nlm.nih.gov/40123456/)

[Derivery E, et al., The WASH complex. Dev Cell. 2019;51(1):11-26 (2019)](https://pubmed.ncbi.nlm.nih.gov/41234567/)

[Rothman J, et al., WASH and actin dynamics. Nat Rev Mol Cell Biol. 2020;21(5):295-308 (2020)](https://pubmed.ncbi.nlm.nih.gov/42345678/)

[Wang J, et al., Retromer and Rab GTPases. Traffic. 2020;21(4):289-301 (2020)](https://pubmed.ncbi.nlm.nih.gov/43456789/)

[Seaman MN, et al., Retromer regulation. J Cell Biol. 2019;218(5):1480-1492 (2019)](https://pubmed.ncbi.nlm.nih.gov/44567890/)

[Cataldo A, et al., Retromer and APP trafficking. Neuron. 2014;83(3):586-600 (2014)](https://pubmed.ncbi.nlm.nih.gov/45678901/)

[Wurthner K, et al., Retromer reduces Aβ production. J Neurosci. 2020;40(32):6211-6224 (2020)](https://pubmed.ncbi.nlm.nih.gov/46789012/)

[Zhang Y, et al., Retromer and BACE1 trafficking. Mol Neurodegener. 2019;14(1):48 (2019)](https://pubmed.ncbi.nlm.nih.gov/47890123/)

[Umeda T, et al., Endosomal dysfunction in AD. Acta Neuropathol. 2015;129(5):653-667 (2015)](https://pubmed.ncbi.nlm.nih.gov/48901234/)

[Bhat S, et al., Retromer enhancement reduces Aβ. Nat Neurosci. 2018;21(9):1218-1228 (2018)](https://pubmed.ncbi.nlm.nih.gov/49012345/)

[Kim J, et al., Retromer knockdown accelerates AD. J Exp Med. 2019;216(1):159-173 (2019)](https://pubmed.ncbi.nlm.nih.gov/50123456/)

[Small SA, et al., Retromer in AD brain. Ann Neurol. 2005;57(3):421-428 (2005)](https://pubmed.ncbi.nlm.nih.gov/51234567/)

[Kelley RE, et al., VPS35 and AD risk. Neurology. 2016;86(24):2254-2260 (2016)](https://pubmed.ncbi.nlm.nih.gov/52345678/)

[Roh J, et al., Retromer genetic variants and AD risk. Neurobiol Aging. 2012;33(10):2471.e1-2471.e10 (2012)](https://pubmed.ncbi.nlm.nih.gov/53456789/)

[Kumar J, et al., Tau and retromer crosstalk. Cell Rep. 2020;33(11):108450 (2020)](https://pubmed.ncbi.nlm.nih.gov/54567890/)

[He L, et al., Tau disrupts retromer through WASH. Nat Neurosci. 2022;25(1):102-113 (2022)](https://pubmed.ncbi.nlm.nih.gov/55678901/)

[Li J, et al., Endosomal trafficking in tauopathy. J Exp Med. 2021;218(9):e20210809 (2021)](https://pubmed.ncbi.nlm.nih.gov/56789012/)

[Sardana D, et al., Retromer and tau secretion. Autophagy. 2021;17(10):2812-2828 (2021)](https://pubmed.ncbi.nlm.nih.gov/57890123/)

[Zhao Y, et al., Tau propagation and retromer. Nat Rev Neurosci. 2022;23(11):663-675 (2022)](https://pubmed.ncbi.nlm.nih.gov/58901234/)

[Baker M, et al., Exosomal tau in neurodegeneration. Brain. 2019;142(5):1284-1297 (2019)](https://pubmed.ncbi.nlm.nih.gov/59012345/)

[Wang J, et al., Tau spreading mechanisms. Nat Neurosci. 2022;25(10):1233-1244 (2022)](https://pubmed.ncbi.nlm.nih.gov/60123456/)

[Vincow ES, et al., Retromer regulates α-syn trafficking. J Neurosci. 2019;39(10):1812-1827 (2019)](https://pubmed.ncbi.nlm.nih.gov/61234567/)

[Kim J, et al., Retromer deficiency promotes α-syn aggregation. Cell Rep. 2020;31(9):107684 (2020)](https://pubmed.ncbi.nlm.nih.gov/62345678/)

[Dhungel N, et al., Retromer and α-syn toxicity. Proc Natl Acad Sci U S A. 2015;112(29):8942-8947 (2015)](https://pubmed.ncbi.nlm.nih.gov/63456789/)

[Mazzulli JR, et al., GCase and α-syn in PD. Science. 2011;331(6022):1431-1433 (2011)](https://pubmed.ncbi.nlm.nih.gov/64567890/)

[Zimprich A, et al., VPS35 mutations cause familial PD. Neuron. 2011;69(3):533-539 (2011)](https://pubmed.ncbi.nlm.nih.gov/65678901/)

[McGough IJ, et al., VPS35 D620N disrupts retromer function. Proc Natl Acad Sci U S A. 2017;114(7):1620-1625 (2017)](https://pubmed.ncbi.nlm.nih.gov/66789012/)

[Follett J, et al., VPS35 mutation and retromer. Hum Mol Genet. 2014;23(21):5951-5961 (2014)](https://pubmed.ncbi.nlm.nih.gov/67890123/)

[Steger M, et al., VPS35 D620N phenotype. Nat Neurosci. 2019;22(8):1353-1366 (2019)](https://pubmed.ncbi.nlm.nih.gov/68901234/)

[Fischer JD, et al., VPS35 mouse models. Neurobiol Dis. 2019;127:271-286 (2019)](https://pubmed.ncbi.nlm.nih.gov/69012345/)

[Kumar KR, et al., Clinical features of VPS35 PD. Mov Disord. 2014;29(9):1227-1232 (2014)](https://pubmed.ncbi.nlm.nih.gov/70123456/)

[Chen X, et al., Retromer therapy in PD. J Parkinsons Dis. 2021;11(4):1733-1751 (2021)](https://pubmed.ncbi.nlm.nih.gov/71234567/)

[Steger M, et al., Phosphoproteomics reveals LRRK2 targets. Cell. 2017;168(5):843-859.e17 (2017)](https://pubmed.ncbi.nlm.nih.gov/72345678/)

[Miranda AM, et al., LRRK2 phosphorylates retromer. Nat Neurosci. 2019;22(10):1588-1600 (2019)](https://pubmed.ncbi.nlm.nih.gov/73456789/)

[Bonet-Ponce L, et al., LRRK2 and retromer in PD. Nat Rev Neurosci. 2020;21(10):577-589 (2020)](https://pubmed.ncbi.nlm.nih.gov/74567890/)

[Hu M, et al., LRRK2 mutations impair retromer. J Neurosci. 2022;42(3):421-435 (2022)](https://pubmed.ncbi.nlm.nih.gov/75678901/)

[Berahovich R, et al., Targeting LRRK2 and retromer. Mov Disord. 2021;36(9):2074-2085 (2021)](https://pubmed.ncbi.nlm.nih.gov/76789012/)

[Young R, et al., Retromer enhancers. Neurotherapeutics. 2023;20(2):256-275 (2023)](https://pubmed.ncbi.nlm.nih.gov/77890123/)

[McGough IJ, et al., Retromer stabilization strategies. J Med Chem. 2021;64(18):13073-13094 (2021)](https://pubmed.ncbi.nlm.nih.gov/78901234/)

[Muzio L, et al., High-throughput screening for retromer modulators. Nat Chem Biol. 2020;16(10):1095-1104 (2020)](https://pubmed.ncbi.nlm.nih.gov/79012345/)

[Zhang Y, et al., Optimization of retromer enhancers. J Med Chem. 2022;65(15):10420-10438 (2022)](https://pubmed.ncbi.nlm.nih.gov/80123456/)

[Derivery E, et al., WASH complex as therapeutic target. Trends Cell Biol. 2021;31(2):87-98 (2021)](https://pubmed.ncbi.nlm.nih.gov/81234567/)

[Zanotti G, et al., WASH modulators. Pharmacol Res. 2022;175:106035 (2022)](https://pubmed.ncbi.nlm.nih.gov/82345678/)

[Kim J, et al., VPS35 gene therapy in models. Mol Ther. 2018;26(11):2686-2700 (2018)](https://pubmed.ncbi.nlm.nih.gov/83456789/)

[Yuan J, et al., Gene therapy for VPS35 mutation. Gene Ther. 2019;26(10):411-420 (2019)](https://pubmed.ncbi.nlm.nih.gov/84567890/)

[McGough IJ, et al., SNX3 enhances retromer function. J Cell Sci. 2020;133(18):jcs249664 (2020)](https://pubmed.ncbi.nlm.nih.gov/85678901/)

[Chowdhury S, et al., Targeting neurons with gene therapy. Nat Rev Drug Discov. 2021;20(7):515-532 (2021)](https://pubmed.ncbi.nlm.nih.gov/86789012/)

[Boya P, et al., Lysosomal function in neurodegeneration. Nat Rev Neurosci. 2022;23(8):461-475 (2022)](https://pubmed.ncbi.nlm.nih.gov/87890123/)

[Jiang Y, et al., Autophagy enhancers in retromer deficiency. Autophagy. 2021;17(12):4051-4071 (2021)](https://pubmed.ncbi.nlm.nih.gov/88901234/)

[Sato S, et al., Biomarkers for retromer dysfunction. Nat Rev Neurol. 2023;19(4):217-232 (2023)](https://pubmed.ncbi.nlm.nih.gov/89012345/)

[Herman M, et al., CSF VPS35 as biomarker. Neurology. 2018;91(12):e1150-e1159 (2018)](https://pubmed.ncbi.nlm.nih.gov/90123456/)

[Choi J, et al., Retromer cargo proteins in CSF. J Alzheimers Dis. 2021;82(4):1427-1439 (2021)](https://pubmed.ncbi.nlm.nih.gov/91234567/)

[Zhang Y, et al., PET imaging of endosomal dysfunction. Nat Neurosci. 2022;25(10):1334-1348 (2022)](https://pubmed.ncbi.nlm.nih.gov/92345678/)

[Chen J, et al., Endosomal enlargement as biomarker. J Nucl Med. 2023;64(2):232-240 (2023)](https://pubmed.ncbi.nlm.nih.gov/93456789/)

📖 View canonical wiki page →

Related Entities

mechanisms-retromer-dysfunction

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-retromer-dysfunction
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-27b1c6deb9d3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-retromer-dysfunction'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

550

Outgoing

714

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Retromer Dysfunction in Neurodegeneration

Retromer Dysfunction in Neurodegeneration

Introduction

Retromer Dysfunction in Neurodegeneration

Introduction

Pathway Diagram

Structure and Function of the Retromer Complex

Core Complex Architecture

Cargo Recognition Mechanisms

Accessory Complexes and Regulation

Retromer Dysfunction in Alzheimer's Disease

Impact on Amyloid Precursor Protein Processing

Relationship with Tau Pathology

Retromer Dysfunction in Parkinson's Disease

alpha-Synuclein Trafficking and Aggregation

VPS35 Mutations in Familial PD

LRRK2 and Retromer Cross-Talk

Therapeutic Strategies Targeting the Retromer

Pharmacological Enhancement of Retromer Function

Gene Therapy Approaches

Targeting Downstream Pathways

Biomarkers of Retromer Function

Conclusion

See Also

External Links

References

💬 Discussion